DVAX

Dynavax Technologies Corporation Healthcare - Drug Manufacturers - Specialty & Generic Investor Relations →

NO
28.8% ABOVE
↓ Approaching Was 29.1% last week
-15% -10% -5% 0% 5% 10% 15%+
Buy Threshold $12.03
14-Week RSI 88
Rel. Volume (14w) This week's trading vs. the 14-week average 0.5x
Buyers vs. Sellers (14w) Are up-weeks or down-weeks getting more volume? 1.71 — Buyers winning

Dynavax Technologies Corporation (DVAX) closed at $15.50 as of 2026-02-13, trading 28.8% above its 200-week moving average of $12.03. The stock is currently moving closer to the line, down from 29.1% last week. With a 14-week RSI of 88, DVAX is in overbought territory.

Over the past 14 weeks, up-weeks have carried more volume than down-weeks (1.71 buyers-vs-sellers ratio). When trading picks up, it's more often on days the price is rising — buyers are showing more interest than sellers.

Over the past 1099 weeks of data, DVAX has crossed below its 200-week moving average 24 times. On average, these episodes lasted 29 weeks. The average one-year return after crossing below was -11.2%, suggesting these dips have not historically been reliable buying opportunities for this stock.

With a market cap of $1820 million, DVAX is a small-cap stock. The company generates a free cash flow yield of 2.8%. Return on equity stands at -7.1%. The stock trades at 3.4x book value.

Over the past 21.2 years, a hypothetical investment of $100 in DVAX would have grown to $22, compared to $856 for the S&P 500. DVAX has returned -7.0% annualized vs 10.7% for the index, underperforming the broader market over this period.

Free cash flow has been declining at a -43.1% compound annual rate. A deteriorating cash flow trend warrants extra scrutiny — the stock may be cheap for a reason.

Business Health

Annual financials — how the underlying business has performed over the past several years.

Cash Flow Free cash flow & net income ($M)

Revenue Annual revenue ($M) — business growth proxy

Total Debt Balance sheet debt ($M)

ROIC Return on invested capital (%)

FCF Yield Free cash flow / market cap (%) — Yartseva signal

Gross Margin Pricing power & competitive moat (%)

Shares Outstanding Buybacks vs dilution (millions)

Growth of $100: DVAX vs S&P 500

Monthly data normalized to $100 at start. Vertical dashed lines mark 200-week MA touches.

What Happens After DVAX Crosses Below the Line?

Across 24 historical episodes, buying DVAX when it crossed below its 200-week moving average produced an average return of -7.6% after 12 months (median -12.0%), compared to +11.3% for the S&P 500 over the same periods. 30% of those episodes were profitable after one year. After 24 months, the average return was -30.4% vs +20.4% for the index.

Each line shows $100 invested at the moment DVAX crossed below its 200-week MA. Bold blue = stock average. Gray dashed = S&P 500 average over same periods.

Advertisement

Historical Touches

DVAX has crossed below its 200-week MA 24 times with an average 1-year return of +-11.2% after recovery.

Crossed BelowRecoveredWeeksMax Depth1-Year ReturnReturn Since Touch
Feb 2005Aug 20052644.9%-3.2%-75.4%
Oct 2005Oct 200534.9%+25.5%-74.5%
Nov 2005Feb 20061332.6%+15.5%-68.9%
Feb 2006Feb 200610.0%-7.6%-73.9%
Apr 2006Oct 20062633.7%-8.0%-73.5%
Feb 2007Feb 20085535.9%-10.7%-73.6%
Mar 2008Dec 201014396.5%-67.5%-26.9%
Aug 2011Aug 201111.0%+77.3%-25.1%
Sep 2011Oct 201138.1%+153.4%-19.7%
Nov 2012Nov 201210.7%-44.7%-36.5%
Feb 2013Jul 201512359.6%-6.1%-21.7%
Oct 2015Nov 201567.2%-54.7%-35.0%
Jan 2016Jan 2016111.2%-79.3%-26.4%
Feb 2016Jul 20177877.7%-81.0%-26.4%
Jan 2018Jan 201824.1%-29.8%-1.6%
Mar 2018Mar 201810.0%-51.5%-5.5%
Apr 2018May 201810.7%-57.6%-5.5%
May 2018Feb 202114179.4%-70.2%-4.3%
Feb 2021Mar 2021316.0%+42.6%+77.1%
Mar 2021Apr 202111.4%+15.7%+59.3%
Apr 2021Aug 20211522.0%-0.7%+61.6%
Apr 2024May 202445.0%-3.5%+38.3%
Jun 2024Nov 20241912.5%-11.8%+38.0%
Apr 2025Dec 20253724.9%N/A+37.8%
Average29+-11.2%

Frequently Asked Questions

Is DVAX below its 200-week moving average?

No. Dynavax Technologies Corporation (DVAX) is currently 28.8% above its 200-week moving average of $12.03. It would need to fall to $12.03 to cross below the line.

What is DVAX's 200-week moving average price?

Dynavax Technologies Corporation's 200-week moving average is $12.03 as of 2026-02-13. This is the average weekly closing price over roughly the last 4 years, and it acts as a long-term trend line. When a stock drops below this level, it can signal that the price has fallen far enough from the long-term trend to attract value-oriented investors.

What happens when DVAX drops below its 200-week moving average?

DVAX has crossed below its 200-week moving average 24 times in our data. The average one-year return after these crossings was -11.2%, meaning the dips were not reliable buying signals for this particular stock. These episodes lasted 29 weeks on average.

Is DVAX a good value right now?

Here's what our data says about DVAX as of 2026-02-13: The stock is above its 200-week moving average, so it doesn't currently meet our primary signal. The 14-week RSI is 88 (overbought). Free cash flow yield is 2.8%. Return on equity is -7.1%. Price-to-book is 3.4x. This is not a buy or sell recommendation — always do your own research.

How does DVAX compare to the S&P 500?

Over the past 21.2 years, $100 invested in DVAX would have grown to $22, compared to $856 for the S&P 500. That's -7.0% annualized vs 10.7% for the index. DVAX has underperformed the broader market over this period.

Not financial advice. This is an educational tool. Past performance does not guarantee future results. Do your own research before making investment decisions.

Data as of week of 2026-02-13